News Daily News Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF L.A. McKeown December 07, 2021
News Conference News AHA 2021 Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF Michael O'Riordan November 19, 2021
News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Conference News TCT 2021 GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF Michael O'Riordan November 06, 2021
News Daily News Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label Todd Neale September 20, 2021
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021
News Conference News HRS 2021 Heart Failure Patients With AF Benefit From Early Rhythm Control Shelley Wood July 30, 2021
News Conference News ESC Heart Failure 2021 Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR Shelley Wood July 06, 2021
News Daily News Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results Todd Neale July 06, 2021
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Daily News Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF Michael O'Riordan April 15, 2021
News Daily News New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF Todd Neale February 16, 2021